Showing results (341-350 of 422) with videos related to
Sort By:
Pageof 43
Human Molecular Genetics|May 20, 2014
A C. elegans model of human α1-antitrypsin deficiency links components of the RNAi pathway to misfolded protein turnoverOlivia S Long, Joshua A Benson, Joon Hyeok Kwak, et al.Vaccine|March 6, 1999
Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccineR Edelman, K Palmer, K G Russ, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid TumorsGeorge D Demetri, Jason J Luke, Antoine Hollebecque, et al.Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.Journal of the American College of Nutrition|March 12, 2015
The addition of beta-hydroxy-beta-methylbutyrate and isomaltulose to whey protein improves recovery from highly demanding resistance exerciseWilliam J Kraemer, David R Hooper, Tunde K Szivak, et al.The Journal of Infectious Diseases|January 19, 2013
A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trialAnna P Durbin, Beth D Kirkpatrick, Kristen K Pierce, et al.JCI Insight|March 7, 2023
Microfluidic device facilitates in vitro modeling of human neonatal necrotizing enterocolitis-on-a-chipWyatt E Lanik, Cliff J Luke, Lila S Nolan, et al.Journal for Immunotherapy of Cancer|March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumorsNikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib StudyFunda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in MelanomaDaniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.Pageof 43